TD Private Client Wealth LLC Decreases Stake in Sanofi (NASDAQ:SNY)

TD Private Client Wealth LLC lessened its stake in Sanofi (NASDAQ:SNY) by 5.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 101,796 shares of the company’s stock after selling 6,352 shares during the quarter. TD Private Client Wealth LLC’s holdings in Sanofi were worth $5,867,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. GFS Advisors LLC increased its holdings in Sanofi by 1,017.9% in the third quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock valued at $738,000 after buying an additional 11,655 shares in the last quarter. Legacy Capital Wealth Partners LLC increased its stake in Sanofi by 114.2% in the 3rd quarter. Legacy Capital Wealth Partners LLC now owns 24,274 shares of the company’s stock valued at $1,399,000 after purchasing an additional 12,942 shares in the last quarter. Icon Wealth Advisors LLC raised its holdings in Sanofi by 7,954.4% during the third quarter. Icon Wealth Advisors LLC now owns 292,779 shares of the company’s stock worth $16,873,000 after purchasing an additional 289,144 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its position in Sanofi by 15.2% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 116,917 shares of the company’s stock worth $5,673,000 after purchasing an additional 15,439 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Sanofi in the third quarter valued at $8,728,000. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Trading Down 0.7 %

Shares of SNY opened at $48.08 on Wednesday. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The stock’s 50-day moving average is $51.53 and its two-hundred day moving average is $52.12. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The stock has a market cap of $122.02 billion, a PE ratio of 24.53, a P/E/G ratio of 1.23 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. During the same period last year, the business earned $2.55 EPS. The business’s revenue was up 12.3% on a year-over-year basis. Equities analysts forecast that Sanofi will post 4.27 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

SNY has been the topic of several recent research reports. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Sanofi currently has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.